The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Clinical Trial of Clarithromycin for Cutaneous (Disseminated) Infection due to Mycobacterium chelonae

Richard J. Wallace, MD; David Tanner, MD; Patrick J. Brennan, MD; and Barbara A. Brown, MS, MT(ASCP)SM
[+] Article, Author, and Disclosure Information

From the University of Texas Health Center at Tyler, Tyler, Texas; Duke University Medical Center, Durham, North Carolina; the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Requests for Reprints: Richard J. Wallace, Jr., MD, Department of Microbiology, The University of Texas Health Center, P.O. Box 2003, Tyler, TX 75710. Acknowledgments: The authors thank Richard Drew for administrative help and the following physicians who allowed the authors to help follow their patients: John Dunkel, Huntsville, Alabama; Audrey French, Burlington, Vermont; Beverly Alston, Chapel Hill, North Carolina; Charles Bryan, Columbia, South Carolina; Clay Dunagan, St. Louis, Missouri; Judith Schlay, Denver, Colorado; Steve Dummer, Nashville, Tennessee; John Ladd, Corvallis, Oregon; and Mary Aspen, Orange, California. Grant Support: In part by a grant from Abbott Laboratories, Chicago, Illinois.

Copyright 2004 by the American College of Physicians

Ann Intern Med. 1993;119(6):482-486. doi:10.7326/0003-4819-119-6-199309150-00006
Text Size: A A A

Objective: To determine if clarithromycin monotherapy is safe and effective in treating cutaneous disease (especially disseminated disease) due to Mycobacterium chelonae (formerly M. chelonae subspecies chelonae).

Design: An open, noncomparative trial of clarithromycin as single-drug therapy.

Setting: Nationwide referrals.

Patients: Culture-positive patients whose M. chelonae came from a cutaneous source and whose isolate was submitted to a single referral laboratory for susceptibility testing.

Intervention: Clarithromycin, 500 mg twice a day by mouth for 6 months. No attempt was made to alter use of immunosuppressive drugs.

Main Outcome Measures: Acid-fast bacilli smears and cultures of skin lesions during and after treatment, with monitoring of clinical response, side effects, and development of new lesions.

Results: Fourteen patients (10 with disseminated disease) were enrolled in the study and completed at least 3 months of therapy. Underlying diseases included rheumatoid arthritis, other autoimmune disorders, and organ transplantation. All were taking corticosteroids (93%) or cyclophosphamide (7%). All patients had an excellent response to therapy, with only mild side effects from the drug. Two patients died of other diseases after improving clinically but while still taking medication. One noncompliant patient who prematurely discontinued therapy after 3.5 months relapsed 1 month later with an isolate resistant to clarithromycin. The remaining 11 patients have all completed therapy given for a mean of 6.8 months (range, 4.5 to 9 months). Therapy has been discontinued for 9 of the 11 patients for at least 6 months (mean, 7.1 months; range, 6 to 12 months), with no evidence of relapse. No remaining patient had positive acid-fast bacilli smears or cultures of skin lesions after 1 month of therapy.

Conclusions: Clarithromycin may be the drug of choice for cutaneous (disseminated) disease due to M. chelonae, although more patients with long-term clinical follow-up need to be studied.


Grahic Jump Location
Figure 1.
Disseminated skin disease.Left.Right.

Before treatment. Multiple skin lesions of the leg in patient 1 who had underlying rheumatoid arthritis. During treatment. Close-up of the same area of the leg of patient 1 after 2 months of therapy with clarithromycin.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Mycobacterium chelonae osteomyelitis.Left.M. chelonaeRight.

Before treatment. Cellulitis-osteomyelitis caused by infection at the site of a previous transmetatarsal amputation in a 46-year-old man (patient 7) receiving cyclophosphamide for rheumatoid arthritis. After treatment. Follow-up photograph of the same foot after 6 months of therapy with clarithromycin.

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.